JP Morgan analyst Steven Alexopoulos downgrades Huntington Bancshares (NASDAQ:HBAN) from Overweight to Neutral and lowers the price target from $17.5 to $14.5.
IceCure Medical Reports Q1 2023 Financial & Operational Results; Q1 Revenue $0.71M Vs $0.75M YoY; Q1 EPS $(0.08) Vs $(0.12) YoY
Financial Results as of and for the Three Months Ended March 31, 2023For the three months ended March 31, 2023, the Company reported revenue of $0.71 million compared to revenue of $0.75 million for the three months
